寡转移非小细胞肺癌局部巩固治疗对比维持治疗或观察:多中心II期随机研究长期结果
本多中心II期随机试验纳入一线系统治疗后3个月以上未进展的IV期NSCLC且转移灶≤3个的患者,1:1随机接受局部巩固治疗(LCT)或维持治疗/观察(MT/O)。LCT组中位PFS为14.2个月 vs MT/O组4.4个月(P=.022),中位OS为41.2个月 vs 17.0个月(P=.017),未观察到新增≥3级毒性。
要点
- LCT较MT/O延长中位PFS(14.2个月 vs 4.4个月,P=.022)和中位OS(41.2个月 vs 17.0个月,P=.017)。
- LCT组进展后生存更长(37.6个月 vs 9.4个月,P=.034)。
- 未观察到新增≥3级毒性。
核心结论
- 在一线系统治疗后未进展的寡转移NSCLC患者中,LCT较MT/O延长PFS和OS。
研究设计与样本
- 多中心、随机、II期试验,入组IV期NSCLC、转移灶≤3个、一线系统治疗后3个月以上未进展的患者。
- 患者1:1随机分配至维持治疗或观察(MT/O)组或局部巩固治疗(LCT)组,LCT针对所有活动性疾病部位。
- 主要终点为PFS,次要终点为OS、毒性和新发病灶出现。
- 数据安全与监查委员会在49例患者随机分组后因LCT组PFS获益显著而建议提前终止试验。
主要发现
- 中位随访更新为38.8个月(范围28.3至61.4个月)。
- 中位PFS:LCT组14.2个月(95%CI 7.4至23.1个月) vs MT/O组4.4个月(95%CI 2.2至8.3个月),P=.022。
- 中位OS:LCT组41.2个月(95%CI 18.9个月至未达到) vs MT/O组17.0个月(95%CI 10.1至39.8个月),P=.017。
- 未观察到新增≥3级毒性。
- 进展后生存:LCT组37.6个月 vs MT/O组9.4个月,P=.034。
关键数值与推荐
- 所有分析为双侧,P值小于.10视为显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our previously published findings reported that local consolidative therapy (LCT) with radiotherapy or surgery improved progression-free survival (PFS) and delayed new disease in patients with oligometastatic non-small-cell lung cancer (NSCLC) that did not progress after front-line systemic therapy. Herein, we present the longer-term overall survival (OS) results accompanied by additional secondary end points. PATIENTS AND METHODS: This multicenter, randomized, phase II trial enrolled patients with stage IV NSCLC, three or fewer metastases, and no progression at 3 or more months after front-line systemic therapy. Patients were randomly assigned (1:1) to maintenance therapy or observation (MT/O) or to LCT to all active disease sites. The primary end point was PFS; secondary end points were OS, toxicity, and the appearance of new lesions. All analyses were two sided, and P values less than .10 were deemed significant. RESULTS: The Data Safety and Monitoring Board recommended early trial closure after 49 patients were randomly assigned because of a significant PFS benefit in the LCT arm. With an updated median follow-up time of 38.8 months (range, 28.3 to 61.4 months), the PFS benefit was durable (median, 14.2 months [95% CI, 7.4 to 23.1 months] with LCT v 4.4 months [95% CI, 2.2 to 8.3 months] with MT/O; P = .022). We also found an OS benefit in the LCT arm (median, 41.2 months [95% CI, 18.9 months to not reached] with LCT v 17.0 months [95% CI, 10.1 to 39.8 months] with MT/O; P = .017). No additional grade 3 or greater toxicities were observed. Survival after progression was longer in the LCT group (37.6 months with LCT v 9.4 months with MT/O; P = .034). Of the 20 patients who experienced progression in the MT/O arm, nine received LCT to all lesions after progression, and the median OS was 17 months (95% CI, 7.8 months to not reached). CONCLUSION: In patients with oligometastatic NSCLC that did not progress after front-line systemic therapy, LCT prolonged PFS and OS relative to MT/O.
引用
- Gomez DR, Tang C, Zhang J, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019. PMID: 31067138. doi:10.1200/JCO.19.00201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。